Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
15.24
+0.34 (2.28%)
At close: Apr 14, 2026, 4:00 PM EDT
15.05
-0.19 (-1.25%)
Pre-market: Apr 15, 2026, 5:30 AM EDT

Janux Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
9278333,162496548814
Market Cap Growth
-47.33%-73.65%537.19%-9.45%-32.65%-
Enterprise Value
-17.35-113.522,158175.29245.61438.76
Last Close Price
15.2413.8053.5410.7313.1719.73
PE Ratio
--7.54-41.83-8.13-8.66-14.19
PS Ratio
92.7183.33298.6761.4063.64223.74
PB Ratio
0.960.873.091.441.712.22
P/TBV Ratio
0.990.892.811.371.701.27
P/FCF Ratio
--10.01-71.59-9.47-11.10-44.09
P/OCF Ratio
--10.13-72.18-9.81-12.77-47.93
EV/Sales Ratio
--11.35203.8621.6928.52120.64
EV/EBITDA Ratio
-0.73-22.30-2.47-3.71-13.37
EV/EBIT Ratio
-0.72-21.84-2.40-3.66-13.32
EV/FCF Ratio
-1.36-48.86-3.34-4.98-23.77
Debt / Equity Ratio
0.020.020.020.070.080
Debt / EBITDA Ratio
-0.14-0.14-0.24-0.35-0.38-0.01
Debt / FCF Ratio
-0.27-0.27-0.52-0.47-0.51-0.01
Net Debt / Equity Ratio
-0.99-0.99-0.98-0.93-0.94-1.02
Net Debt / EBITDA Ratio
6.076.0710.354.504.5511.42
Net Debt / FCF Ratio
11.3411.3422.696.096.1120.30
Asset Turnover
0.010.010.010.020.020.02
Quick Ratio
38.6738.6758.7226.4019.8129.30
Current Ratio
39.0439.0459.2126.8020.1429.46
Return on Equity (ROE)
-11.48%-11.48%-10.09%-17.53%-18.36%-17.50%
Return on Assets (ROA)
-15.28%-15.28%-13.71%-19.61%-18.04%-16.63%
Return on Invested Capital (ROIC)
-954.78%-954.78%-418.83%-274.23%-530.83%-1126.36%
Return on Capital Employed (ROCE)
-15.61%-15.61%-14.01%-20.42%-18.78%-17.33%
Earnings Yield
-12.26%-13.26%-2.39%-12.30%-11.54%-7.05%
FCF Yield
-8.98%-9.99%-1.40%-10.56%-9.01%-2.27%
Buyback Yield / Dilution
-15.28%-15.28%-22.12%-6.14%-76.24%-2471.21%
Total Shareholder Return
-15.28%-15.28%-22.12%-6.14%-76.24%-2471.21%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q